Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Pastrami on Rye -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (280)	6/3/2008 5:28:47 PM
From: Mike McFarland	Respond to of 379

Dharmacon patents 209.85.173.104 I don't subscribe--so you can find stuff using the google cache for example, trying this gets even more 209.85.173.104 etc 209.85.173.104

To: Mike McFarland who wrote (280)	6/11/2008 8:04:30 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 379

BALTIMORE, May 15 /PRNewswire/ -- Lentigen Corporation announced today that it has received four National Institutes of Health (NIH) small business innovation research (SBIR) grants to collaborate with leading scientists. Through these grants, Lentigen will apply its proprietary lentiviral vector (LV) technology to the development of novel immunotherapeutic treatments for diseases of high unmet medical need: -- Melanoma, with Michael Nishimura, Ph.D, Associate Professor of Surgery, Medical University of South Carolina -- Hepatitis C virus (HCV) infection, also with Dr. Nishimura -- Epstein-Barr virus (EBV)-related diseases, with Adrian Wiestner, M.D./Ph.D., Principal Investigator, National Cancer Institute -- Chronic lymphocytic leukemia (CLL), also with Dr. Wiestner Together with its collaborators, Lentigen will develop lentiviral vectors designed to target specific cells related to each of these diseases. For melanoma, HCV, and EBV, the vectors will transduce T cells, which play a central role in cell-mediated immunity, with proteins known as T cell receptors (TCRs) that have been engineered to attack the targeted disease. For CLL, the vectors will carry weakened cells of this cancer combined with other substances designed to trigger an immune response. "These innovation research grants are enabling us to extend the application of our lentiviral vector technology to a wider range of diseases while working with distinguished researchers to address the urgent need for novel biotherapeutics and vaccines in areas of high unmet medical need," said Tim Ravenscroft, Lentigen's CEO. About Lentigen Corporation Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, ThermoFisher Scientific and The U.S. Army. For further information, visit www.lentigen.com lentigen.com Lentigen Media Contact: Gregory Tiberend gtiberend@rlcinc.com Meghan Feeks mfeeks@rlcinc.com Richard Lewis Communications, Inc. 212-827-0020 SOURCE Lentigen Corporation